Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clgc.2018.11.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Outcomes of Onco-Testis Sperm Extraction at the Time of Radical Orchiectomy.
Urology
December 2024
Sexual & Reproductive Medicine Program, Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Objective: To evaluate outcomes of onco-testis sperm extraction (TESE) and to define potential predictors of successful surgical sperm retrieval (SSR).
Methods: For this study, we examined all men (i) diagnosed with a testicular mass, (ii) who had azoospermia, and (iii) who underwent a radical orchiectomy and onco-TESE. Our institutional database of testicular cancer (TCA) patients was reviewed.
Case report: Metastatic melanoma derived from a somatic-type malignant transformation of a mediastinal teratoma treated with immune checkpoint inhibitors.
Front Oncol
November 2024
Medical Oncology Unit, Department of Systems Medicine, University Tor Vergata, Rome, Italy.
The treatment of patients affected by a teratoma with somatic-type malignancy (STM) is challenging, since they are characterized by a poor prognosis, due to chemoresistance to standard cisplatin-based regimens. Only five more case reports were described for melanomatous STM and for which there are no data available for efficacy evidences of immune checkpoint inhibitors in this setting. Here we report the case of a patient with an initial diagnosis of mediastinal pure seminoma at the first biopsy.
View Article and Find Full Text PDFFrench AFU Cancer Committee Guidelines - Update 2024-2026: Testicular germ cell cancer.
Fr J Urol
November 2024
Comité de Cancérologie de l'Association Française d'Urologie, groupe organes génitaux externes, Maison de l'Urologie, 11, rue Viète, 75017 Paris, France; Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitié-Salpêtrière Hospital, 75013 Paris, France.
Article Synopsis
- The objective of the review is to update guidelines for managing testicular germ cell tumors (TGT) based on recent literature from 2022.
- Initial diagnosis involves clinical exam, serum marker levels (AFP, hCG, LDH), and imaging techniques like ultrasound and CT scans; treatment starts with inguinal orchiectomy which helps in defining the tumor stage and treatment approach.
- For specific stages of the tumors, treatment strategies vary, including surveillance for stage I seminomas, risk-adapted options for stage I non-seminomatous tumors, and chemotherapy for metastatic cases, with additional measures like radiotherapy for certain seminoma stages.
Article Synopsis
- The case report details a rare occurrence of a postpubertal-type teratoma in a 48-year-old male, which appeared as a late recurrence of a previously diagnosed seminoma following testicular surgery six years earlier.
- Imaging tests showed a retroperitoneal tumor with unusual characteristics, leading to a biopsy that indicated a high-grade malignant tumor, prompting neoadjuvant chemotherapy that helped shrink the tumor before surgical removal.
- Further analysis revealed that the original seminoma diagnosis overlooked a mixed germ cell tumor component, underscoring the need for comprehensive histological evaluations in testicular germ cell tumors to better inform prognosis and treatment options.
Article Synopsis
- The study investigates the occurrence of rete hyperplasia and hyaline globules in germ cell tumors, with a focus on their potential to mimic yolk sac tumors, noting a significant misdiagnosis risk over the years.
- Out of 348 evaluated orchiectomies, 30% showed rete hyperplasia and/or hyaline globules, often without any yolk sac tumor component, suggesting a complexity in tumor classifications.
- The findings highlight the importance of accurately identifying these histological features, as they may indicate underlying testicular obstruction due to the tumor, which is crucial for proper treatment decisions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!